Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD

1,314 views

Published on

Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.

Dr. Luc Truyen, MD, PhD, VP Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against !lzheimer’s Disease

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,314
On SlideShare
0
From Embeds
0
Number of Embeds
713
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD

  1. 1. Brian Jackson, Untitled 6 Artwork from Reflections Art in Health I have been impressed with the urgency of doing. Knowing is not enough; we must apply. Being willing is not enough; we must do. –Leonardo da Vinci Luc Truyen MD PhD VP Neuroscience External Affairs Janssen and Chair, Global Fight against Alzheimer’s Disease, Johnson & Johnson Program Director, Global Alzheimer’s Platform Global Collaboration: key to conquering Alzheimer’s Disease
  2. 2. Disclaimer The opinions expressed in this presentation are those of the presenter only and do not necessarily reflect the positions or opinions of Janssen Research and Development, L.L.C. or any other individual or affiliate of Johnson & Johnson. The presenter makes no warranties with respect to the accuracy of the data or materials presented herein. All information is provided for informational purposes only and does not constitute advice regarding clinical research-related activities.
  3. 3. Photograph by Judith Fox from I Still Do: Loving and Living with Alzheimer's We need to change the dialogue: From the 70 year old patient with Alzheimer’s Dementia To the 40 year old person with Alzheimer’s Disease
  4. 4. Key needs to get to ‘disease interception’  Increased investment in basic science  Incentivized innovators  Identifying and capturing the right subjects for trials – Clinimetrics – Diagnostics and Biomarkers – ‘Registries’  Translational infrastructure – Registries to trial ready cohorts – Sites that are qualified and ready with access to required tech – Effective trial designs: learn fast, confirm efficiently  Relevant outcomes – Surrogate markers – Sensitive cognitive measures – Economic impact models  A convergent, synchronized regulatory and payor environment
  5. 5. Global Alzheimer’s Platform U.K. Dementia Platform AIBL COLLABORATION DATA SHARING KNOW HOW AMP WW-ADNI We need a global connectome
  6. 6. Thank you

×